Longeveron® Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell

Founder, Chief Science Officer and Executive Chairman, Longeveron MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc.
BioWorld

Cynata’s MSC cells show positive results across variety of delivery systems

The promise of mesenchymal stem cells (MSCs) to heal heart disease could be around the corner thanks to a new delivery method tested by regenerative medicine company Cynata Therapeutics Ltd.
EurekAlert!

Mesenchymal stem cells in cancer immunotherapy: Promises and challenges

Figure 1: Immunomodulatory effects of simulated MSCs. MSCs utilize different molecular mechanisms to suppress (in most cases) or activate immune cells. Orange arrows: inhibition; Green arrows: ...
EurekAlert!

MSC-mediated mitochondrial transfer restores mitochondrial DNA and function in neural progenitor cells of Leber's hereditary optic neuropathy

Patch-clamp recordings demonstrated that LHON neurons, which typically exhibit impaired sodium and potassium currents, showed restored electrophysiological function after co-culture with MSCs.
PharmiWeb

SMART Develops Rapid Iron Measurement to Improve Cartilage Repair through Cell Therapy

A novel, rapid and non‑destructive method was developed to provide real-time insights into iron flux in mesenchymal stromal cells (MSCs) using a micromagnetic resonance relaxometry (µMRR) deviceThe ...